Joined in January 2022. Daniel previously worked at Danish pharmaceutical company Xellia Pharmaceuticals from 2014 to 2021, where he has held several executive positions, and from 2019-2021 was President for Xellia International with responsibility for their activities in EMEA, LATAM and APAC regions. Prior that Daniel worked at LEO Pharma and formerly in consulting with Qvartz (now Bain) and PwC Deals advisory. Daniel holds a Master’s in Economics from University of Copenhagen.